



1623
Bfu

PATENT
DOCKET NO. MTV-037.01

In re Application of:

Seeberger, P.H., et al.

Application No: 10/054,724

Filed: January 22, 2002

For: Solid- and Solution-Phase Synthesis of
Heparin and Other
Glycosaminoglycans

Art Unit: 1623

Examiner: Krishnan, G.

Certificate of Mailing

I hereby certify that this "Supplemental Information Disclosure Statement" is being deposited with the U. S. Postal Service as First Class Mail with sufficient postage on the date set forth below in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

August 16, 2004

Date of Signature and Mail Deposit

By:

Shirine Darvish

Shirine Darvish

Attention: Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the publications are enclosed.

08/20/2004 WASFAW1 00000010 10054724

01 FC:1806

180.00 OP

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- ☐ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☒ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☒ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.


It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Respectfully submitted,



Date: August 16, 2004

Dana M. Gordon, Ph.D.
Reg. No.44,719
Attorney/Agent for Applicant(s)
Foley Hoag LLP
155 Seaport Boulevard
Boston, Massachusetts 02210-2600
Tel. No. (617) 832-1000
Fax No. (617) 832-7000

Form PTO-1449

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i> AUG 19 2004 PATENT & TRADEMARK OFFICE	Docket Number (Optional) MTV-037.01 (20021-3701)	Application Number 10/054,724
	Applicant Seeberger et al.	
	Filing Date January 22, 2002	Group Art Unit 1623

U.S. PATENT DOCUMENTS

EX INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS*(Including Author, Title, Date, Pertinent Pages Etc.)*

BQ	Westman, J., et al., "Synthesis and Fibroblast Growth Factor Binding Of Oligo-Saccharides Related To Heparin and Heparan Sulphate", J. Carbohydrate Chemistry, 14(1), 95-113 (1995)
BR	Nilsson, M., et al., "Synthesis of the methyl glycosides of a tri- and a tetra-saccharide related to heparin and heparan sulphate", Carbohydrate Research, 246 (1993) 161-172
BS	Ichikawa, Y., et al., "Synthesis, From Cellobiose, Of A Trisaccharide Closely Related To The GlcNAc-GlcA-GlcN Segment Of The Anti-Thrombin-Binding Sequence of Heparin", Carbohydrate Research, 141 (1985) 273-282
BT	Jauranda, G., et al., "Biologically Active Heparin-Like Fragments With A "Non-Glycosamino" Glycan Structure. Part 1: A Pentasaccharide Containing A 3-O-Methyl Iduronic Acid Unit", Bioorganic & Medicinal Chemistry Letters, Vol. 2, No. 9, pp. 897-900, 1992
BU	Kovensky, J., et al., "A Synthetic Heparan Sulfate Pentasaccharide, Exclusively Containing L-Iduronic Acid, Displays Higher Affinity for FGF-2 than its D-Glucuronic Acid-Containing Isomers", Bioorganic & Medicinal Chemistry 7 (1999) 1567-1580
BV	Lei, P.S., et al., "Synthesis of 3-Deoxy-L-iduronic Acid Containing Heparin Pentasaccharide to Probe the Conformation of the Antithrombin III Binding Sequence", Bioorganic & Medicinal Chemistry 6 (1998) 1337-1346
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE